Founded in 2016 by three PhD students, Alcinous Pharmaceuticals harnesses big data in a novel approach to design and develop therapeutic drugs aimed at aggressive cancers.

What: Pharmaceutical drug design startup

Innovation: Use computer-aided drug design to improve cancer therapies.

Who: URI graduate students Nicholas DaSilva, Kenneth Rose, and Benjamin Barlock; and URI professor David Worthen.

Market: Cancer treatment

Idea: Use computer technology to sort through many drug-binding targets to identify drugs that will be highly effective and well tolerated.

Notes: Awarded a state Innovation Voucher to work with Prof. Brenton deBoef to prove that these computer designed molecules can be produced in the laboratory.

Alcinous Pharmaceuticals Website

More about Alcinous Pharmaceuticals

Video from Commerce RI: